Varex Imaging (VREX) Q1 2026: Industrial Segment Jumps 17% as Cargo Systems Drive Growth Visibility
Varex Imaging’s first quarter marked a clear inflection in industrial growth, fueled by robust cargo systems demand and a return to medical innovation cycles. The company’s evolving modality-based approach and India manufacturing ramp signal a strategic shift toward deeper integration and regional differentiation. Management’s confident tone is underpinned by a broadening pipeline and operational investments that position Varex for recurring, system-level wins into fiscal 2027 and beyond.
Summary
- Industrial Segment Momentum: Cargo systems and non-destructive testing drove outperformance and pipeline depth.
- Modality Integration Strategy: Transition to subsystem offerings is deepening customer engagement and design-win visibility.
- India Manufacturing Leverage: Regional production is emerging as a differentiator for global and domestic customers.
Business Overview
Varex Imaging is a global leader in X-ray imaging components and subsystems, serving medical and industrial markets. The company generates revenue through sales of X-ray tubes, digital detectors, linear accelerators, and related software and hardware, with major segments in Medical Imaging (CT, mammography, radiography, fluoroscopy, dental, oncology) and Industrial Imaging (cargo security, non-destructive testing, food inspection). Medical comprised 69% and Industrial 31% of Q1 revenue, reflecting a diversified business model anchored in OEM partnerships and recurring subsystem integration.
Performance Analysis
Varex delivered a 5% year-over-year revenue increase, driven by a standout 17% rise in the Industrial segment, primarily from cargo systems and non-destructive testing solutions. Medical segment revenue was stable, with CT and mammography modalities showing relative strength, while dental and oncology lagged. Notably, non-GAAP gross margin reached the high end of guidance at 34%, benefiting from favorable sales mix, though year-over-year comparison was muted by prior-year customs duty refunds.
Regionally, the Americas led with 17% growth, reflecting strong industrial shipments, while EMEA posted a 7% increase and APAC declined 7%. China remained a resilient contributor, accounting for 17% of total revenue. Operationally, inventory increased to support anticipated industrial demand and new product ramps, driving a net operating cash outflow. Adjusted EBITDA margin expanded to 14%, and leverage remained moderate at 1.9x trailing EBITDA.
- Industrial Outperformance: Cargo security and non-destructive testing platforms were the primary growth engines, with repeat orders validating product leadership.
- Medical Stability with Modality Divergence: CT and mammography outperformed, while radiography and dental trailed, reflecting cyclical and regional demand dynamics.
- Inventory and Cash Flow Dynamics: Elevated inventory levels are a strategic investment to support ramping industrial programs and India qualification cycles, with normalization targeted in coming quarters.
Overall, the quarter showcased Varex’s ability to capitalize on industrial tailwinds and position for future medical subsystem wins, albeit with near-term working capital and margin complexity.
Executive Commentary
"Our cargo systems business continues to be a bright spot with multiple installations during the quarter in various countries... Our customer base has long considered our linear accelerator technology as best in class, and we view repeat orders like this as a testament to our success of deployment and performance of our new systems."
Sunny Sanyal, President and CEO
"Gross margin in Q1 was 34% at the high end of our expectations driven by favorable product sales mix... The increase in inventory during the quarter will support anticipated demand across industrial segment, including new product ramps and cargo system deliveries. As those programs progress, our aim is to normalize our inventories."
Sam Maheshwari, CFO
Strategic Positioning
1. Modality-Based Subsystem Integration
Varex is shifting from component sales to integrated subsystem solutions, offering tubes, detectors, generators, and software as bundled imaging chains tailored to specific modalities (CT, radiography, mammography). This approach enhances customer value, accelerates time-to-market, and locks in multi-year design wins, deepening OEM partnerships and recurring revenue streams.
2. India Manufacturing as a Strategic Lever
The ramp of factories in Vizag and Pune positions Varex to supply both domestic and global markets with “Made in India” detectors and tubes. Regional content is becoming a critical differentiator for OEMs expanding in India and emerging markets, supporting both cost competitiveness and regulatory alignment. While near-term P&L burden is evident, management frames this as an investment in long-term growth and margin expansion.
3. Industrial Segment Diversification
Strength in cargo security and non-destructive testing is broadening Varex’s industrial revenue base, with photon counting technologies and linear accelerators enabling higher-margin service opportunities over the product lifecycle. The business remains tender-driven and episodic, but the pipeline supports potential for sustained double-digit growth, subject to customer delivery timing.
4. Medical Innovation Cycle Re-Engagement
Customer engagement at RSNA highlighted a pivot from COVID-driven maintenance to new product development and commercialization. Varex is positioned to benefit from renewed OEM investment in next-generation platforms, particularly in CT and radiography, with design-in opportunities expected to convert to revenue beginning fiscal 2027.
5. Geographic and Customer Mix Resilience
China remains stable as both an end-market and OEM hub, with Varex emphasizing the global expansion of Chinese OEMs. The company’s approach is to treat China as a strategic partner geography, focusing on product fit and competitive positioning rather than macro headlines.
Key Considerations
This quarter’s results reflect a business at the intersection of industrial momentum and medical innovation, underpinned by operational investments and evolving customer engagement models.
Key Considerations:
- Industrial Growth Sustainability: Cargo and NDT order pipelines are robust but remain subject to tender timing and episodic revenue recognition, requiring careful forecasting.
- Medical Segment Recovery: CT strength is offsetting cyclical softness in other modalities, but design-win conversion and regional mix will dictate medium-term growth.
- India Ramp Impact: Manufacturing scale-up is a near-term P&L drag but is expected to drive cost competitiveness and market access in coming years.
- Margin Leverage: Product and regional mix, along with service attach rates in industrial, are the primary levers for gross margin expansion.
- Working Capital Management: Elevated inventory and associated cash outflows will need to normalize as program ramps convert to deliveries and receivables.
Risks
Varex faces several material risks, including: episodic industrial order cycles, regional macro and regulatory shifts (especially in China and India), execution risk in manufacturing ramp and subsystem integration, and working capital drag from inventory build. Management’s optimism is grounded in pipeline visibility, but tender-driven industrial revenue and medical design-in timing remain outside direct control, introducing variability to near-term results.
Forward Outlook
For Q2 2026, Varex guided to:
- Revenue of $210 to $225 million
- Non-GAAP EPS of $0.15 to $0.25
For full-year 2026, management maintained a cautious but positive tone, signaling:
- Stable medical segment with CT strength
- Potential for double-digit industrial growth, contingent on customer delivery timing
Management emphasized continued customer engagement, innovation pipeline conversion, and the importance of India as both a growth and margin lever.
Takeaways
Varex’s Q1 sets a clear tone for 2026: industrial momentum, medical subsystem integration, and strategic manufacturing investments are converging to shape a more resilient, recurring-revenue business model.
- Industrial segment outperformance: Cargo systems and NDT are validating Varex’s technology and supporting near-term growth, but episodic order flow will require ongoing vigilance.
- Medical innovation cycle re-engagement: RSNA engagement and modality-based integration position Varex for multi-year design wins, with revenue conversion expected to accelerate in fiscal 2027.
- India ramp as a differentiator: Near-term cost drag is offset by strategic positioning for global OEM supply and domestic market access, supporting margin and growth optionality.
Conclusion
Varex Imaging’s Q1 2026 results reflect a company executing on industrial tailwinds while laying the groundwork for deeper medical integration and regional manufacturing leverage. While working capital and order timing introduce volatility, the strategic direction is clear: subsystem integration, global diversification, and operational scale-up are building a foundation for durable, multi-cycle growth.
Industry Read-Through
The quarter’s results reinforce a broader industry pivot toward subsystem integration and regional manufacturing as competitive differentiators in imaging and industrial inspection. OEMs and component suppliers across medtech and industrial verticals should note the value of deeper design-win engagement and the growing importance of local content in emerging markets. Industrial imaging’s episodic order flow and medical’s renewed innovation cycle may signal similar dynamics for peers exposed to tender-driven end-markets and OEM platform refreshes. The ability to flex manufacturing footprints and deliver integrated solutions will increasingly separate industry leaders from pure-play component providers in the next cycle.